Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® (semaglutide 2.4mg), in Singapore. The treatment received regulatory ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

A long-term investor in Apple (AAPL) might be perfectly thrilled at the stock's performance. It has returned 663% over the past 10 years, compared with a return of 261% for the S&P 500 SPX. And ...

When Amy Schumer realized Ozempic and Wegovy had harmful side effects for her, she didn’t let that deter her from trying other prescriptions to lose ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

A New Zealand bariatric surgeon cautions that Wegovy, a new weight-loss drug, isn't a magic bullet for obesity. While it can trigger initial weight loss, long-term success hinges on lifestyle changes ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.